FDA Approves Label Update for Dulaglutide to Include Use in Combination With Basal Insulin

Date: 
February, 2017
February 8, 2017. The US Food and Drug Administration has approved a label update for the glucagon-like-1 (GLP-1) receptor agonist dulaglutide. Dulaglutide is now approved for use in combination with basal insulin in adults with type 2 diabetes. This update makes dulaglutide the first GLP-1 receptor agonist indicated for combination use with mealtime insulin or basal insulin.